{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:53:00Z","timestamp":1781848380820,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005941","name":"Dietmar Hopp Stiftung","doi-asserted-by":"publisher","award":["1DH2211236"],"award-info":[{"award-number":["1DH2211236"]}],"id":[{"id":"10.13039\/501100005941","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ACCELERATE","award":["101056190"],"award-info":[{"award-number":["101056190"]}]},{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40290-026-00607-z","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:00:14Z","timestamp":1777896014000},"page":"209-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paediatric Phase I\/II Clinical Trial Assessments Under the New EU Clinical Trial Regulation: A Descriptive Analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4751-1682","authenticated-orcid":false,"given":"Laura","family":"Fankhauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Ligas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette Solli","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Lunzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Al","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Benchetrit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Kopp-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Karres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5274-910X","authenticated-orcid":false,"given":"Cornelis M.","family":"van Tilburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"3","key":"607_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/2159-8290.Cd-20-0779","volume":"11","author":"TW Laetsch","year":"2021","unstructured":"Laetsch TW, DuBois SG, Bender JG, et al. Opportunities and challenges in drug development for pediatric cancers. Cancer Discov. 2021;11(3):545\u201359. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0779.","journal-title":"Cancer Discov"},{"issue":"3","key":"607_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/s2352-4642(22)00344-3","volume":"7","author":"G Vassal","year":"2023","unstructured":"Vassal G, de Rojas T, Pearson ADJ. Impact of the EU paediatric medicine regulation on new anti-cancer medicines for the treatment of children and adolescents. Lancet Child Adolesc Health. 2023;7(3):214\u201322. https:\/\/doi.org\/10.1016\/s2352-4642(22)00344-3.","journal-title":"Lancet Child Adolesc Health"},{"key":"607_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2019.02.011","volume":"112","author":"DV Neel","year":"2019","unstructured":"Neel DV, Shulman DS, DuBois SG. Timing of first-in-child trials of FDA-approved oncology drugs. Eur J Cancer. 2019;112:49\u201356. https:\/\/doi.org\/10.1016\/j.ejca.2019.02.011.","journal-title":"Eur J Cancer"},{"key":"607_CR4","unstructured":"Directorate-General for Health and Food Safety (European Commission). Study on off-label use of medicinal products in the European Union\u2014Report. Publications Office; 2019."},{"issue":"5","key":"607_CR5","doi-asserted-by":"publisher","first-page":"e1269","DOI":"10.1542\/peds.2011-3565","volume":"130","author":"SK Pasquali","year":"2012","unstructured":"Pasquali SK, Lam WK, Chiswell K, et al. Status of the pediatric clinical trials enterprise: an analysis of the US ClinicalTrials.gov registry. Pediatrics. 2012;130(5):e1269\u201377. https:\/\/doi.org\/10.1542\/peds.2011-3565.","journal-title":"Pediatrics"},{"key":"607_CR6","unstructured":"Regulation (EU) No 536\/2014 of The European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use. In: Official Journal of the European Union L 158 ed 2014. p. 1\u201376."},{"key":"607_CR7","unstructured":"World Medical Association. WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Participants. 2025 [cited 2025 16.08.2025]."},{"key":"607_CR8","unstructured":"Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation (EC) No 726\/2004, In: Official Journal of the European Union L 378\/1 December 2006. p. 1\u201319."},{"key":"607_CR9","unstructured":"European Medicines Agency. ACT EU multi-stakeholder workshop on methodology guidance \u2013 workshop report (2024). EMA\/105992\/2024. [Accessed February 16, 2025]. https:\/\/accelerating-clinical-trials.europa.eu\/our-work\/clinical-trials-methodologies_en."},{"key":"607_CR10","unstructured":"European Commission, European Medicines Agency, Heads of Medicines Agency. Workshop for assessors from NCAs and MRECs on paediatric clinical trials, Meeting report (2025). [Accessed January 28, 2026]. https:\/\/accelerating-clinical-trials.europa.eu\/document\/download\/c51cc028-4323-489a-87c2-598bbebdfffd_en?filename=ACT%20EU%20meeting%20report%20-%20Workshop%20on%20paediatric%20clinical%20trials_0.pdf."},{"key":"607_CR11","unstructured":"ACCELERATE Platform. https:\/\/www.accelerate-platform.org. Accessed 28 Jan 2026."},{"issue":"4","key":"607_CR12","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/cpt.2319","volume":"110","author":"L Beck","year":"2021","unstructured":"Beck L, Witt R, Nesper-Brock M, et al. A study of regulatory challenges of pediatric oncology Phase I\/II trial submissions and guidance on protocol development. Clin Pharmacol Ther. 2021;110(4):1025\u201337. https:\/\/doi.org\/10.1002\/cpt.2319.","journal-title":"Clin Pharmacol Ther"},{"key":"607_CR13","unstructured":"United Nations Statistics Division. UNdata. https:\/\/data.un.org\/. Accessed 28 Jan 2026."},{"issue":"4","key":"607_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.annonc.2020.12.015","volume":"32","author":"G Vassal","year":"2021","unstructured":"Vassal G, Kozhaeva O, Griskjane S, et al. Access to essential anticancer medicines for children and adolescents in Europe. Ann Oncol. 2021;32(4):560\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.015.","journal-title":"Ann Oncol"},{"issue":"11","key":"607_CR15","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/2159-8290.Cd-21-0094","volume":"11","author":"CM van Tilburg","year":"2021","unstructured":"van Tilburg CM, Pfaff E, Pajtler KW, et al. The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets. Cancer Discov. 2021;11(11):2764\u201379. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0094.","journal-title":"Cancer Discov"},{"issue":"33","key":"607_CR16","doi-asserted-by":"publisher","first-page":"8431","DOI":"10.1200\/jco.2005.02.1568","volume":"23","author":"DP Lee","year":"2005","unstructured":"Lee DP, Skolnik JM, Adamson PC. Pediatric phase I trials in oncology: an analysis of study conduct efficiency. J Clin Oncol. 2005;23(33):8431\u201341. https:\/\/doi.org\/10.1200\/jco.2005.02.1568.","journal-title":"J Clin Oncol"},{"issue":"10","key":"607_CR17","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/jamapediatrics.2013.465","volume":"167","author":"JD Momper","year":"2013","unstructured":"Momper JD, Mulugeta Y, Green DJ, et al. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. JAMA Pediatr. 2013;167(10):926\u201332. https:\/\/doi.org\/10.1001\/jamapediatrics.2013.465.","journal-title":"JAMA Pediatr"},{"issue":"3","key":"607_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/annonc\/mdy002","volume":"29","author":"N Gaspar","year":"2018","unstructured":"Gaspar N, Marshall LV, Binner D, et al. Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. Ann Oncol. 2018;29(3):766\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdy002.","journal-title":"Ann Oncol"},{"issue":"4","key":"607_CR19","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s43441-021-00283-y","volume":"55","author":"GJ Noel","year":"2021","unstructured":"Noel GJ, Nelson RM, Bucci-Rechtweg C, et al. Inclusion of adolescents in adult clinical trials: report of the Institute for Advanced Clinical Trials for Children\u2019s Pediatric Innovation Research Forum. Ther Innov Regul Sci. 2021;55(4):773\u20138. https:\/\/doi.org\/10.1007\/s43441-021-00283-y.","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"607_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/17407745221132302","volume":"20","author":"C Bucci-Rechtweg","year":"2023","unstructured":"Bucci-Rechtweg C, Siapkara A, An Haack Bonnet K, et al. Strategies to facilitate adolescent access to medicines: improving regulatory guidance. Clin Trials. 2023;20(1):13\u201321. https:\/\/doi.org\/10.1177\/17407745221132302.","journal-title":"Clin Trials"},{"issue":"7","key":"607_CR21","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.1016\/s1470-2045(17)30442-4","volume":"18","author":"ADJ Pearson","year":"2017","unstructured":"Pearson ADJ, Pfister SM, Baruchel A, et al. From class waivers to precision medicine in paediatric oncology. Lancet Oncol. 2017;18(7):e394\u2013404. https:\/\/doi.org\/10.1016\/s1470-2045(17)30442-4.","journal-title":"Lancet Oncol"},{"issue":"1","key":"607_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1586\/17512433.2014.857600","volume":"7","author":"B Quijano Ruiz","year":"2014","unstructured":"Quijano Ruiz B, Desfontaine E, Arenas-L\u00f3pez S, et al. Pediatric formulation issues identified in Paediatric Investigation Plans. Expert Rev Clin Pharmacol. 2014;7(1):25\u201330. https:\/\/doi.org\/10.1586\/17512433.2014.857600.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"607_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121176","author":"B Faulkner","year":"2020","unstructured":"Faulkner B, Delgado-Charro MB. Cardiovascular paediatric medicines development: have Paediatric Investigation Plans lost heart? Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12121176.","journal-title":"Pharmaceutics"},{"issue":"5","key":"607_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40272-014-0082-4","volume":"16","author":"S Wimmer","year":"2014","unstructured":"Wimmer S, Rascher W, McCarthy S, et al. The EU paediatric regulation: still a large discrepancy between therapeutic needs and approved paediatric investigation plans. Paediatr Drugs. 2014;16(5):397\u2013406. https:\/\/doi.org\/10.1007\/s40272-014-0082-4.","journal-title":"Paediatr Drugs"},{"key":"607_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcped.2024.100190","author":"E Brivio","year":"2024","unstructured":"Brivio E, Karres D, Lesa G, et al. Approved medicines for paediatric solid tumours in Europe: lessons from the life cycle of a paediatric investigation plan. EJC Paediatric Oncology. 2024. https:\/\/doi.org\/10.1016\/j.ejcped.2024.100190.","journal-title":"EJC Paediatric Oncology"},{"issue":"6","key":"607_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40272-017-0261-1","volume":"19","author":"PA Tomasi","year":"2017","unstructured":"Tomasi PA, Egger GF, Pallidis C, et al. Enabling development of paediatric medicines in Europe: 10 years of the EU paediatric regulation. Paediatr Drugs. 2017;19(6):505\u201313. https:\/\/doi.org\/10.1007\/s40272-017-0261-1.","journal-title":"Paediatr Drugs"},{"issue":"7696","key":"607_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Gr\u00f6bner","year":"2018","unstructured":"Gr\u00f6bner SN, Worst BC, Weischenfeldt J, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555(7696):321\u20137. https:\/\/doi.org\/10.1038\/nature25480.","journal-title":"Nature"},{"issue":"9","key":"607_CR28","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/pbc.25044","volume":"61","author":"G Vassal","year":"2014","unstructured":"Vassal G, Fitzgerald E, Schrappe M, et al. Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agenda. Pediatr Blood Cancer. 2014;61(9):1551\u20137. https:\/\/doi.org\/10.1002\/pbc.25044.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"607_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"607_CR30","unstructured":"Paediatric Preclinical Proof of Concept Platform. https:\/\/itccp4.com\/. Accessed 26 Feb 2025."},{"key":"607_CR31","unstructured":"Pediatric Preclinical In Vivo Testing Consortium (PIVOT). https:\/\/preclinicalpivot.org\/. Accessed 26 Feb 2025."},{"key":"607_CR32","unstructured":"European Medicines Agency. Consolidated 3-year rolling work plan for the Non-clinical domain (2024). EMA\/551442\/2024. https:\/\/www.ema.europa.eu\/en\/documents\/other\/consolidated-3-year-rolling-work-plan-non-clinical-domain-2025-2027_en.pdf. Accessed 26 Feb 2025."}],"updated-by":[{"DOI":"10.1007\/s40290-026-00616-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000}}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00607-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00607-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00607-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:29:05Z","timestamp":1781846945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00607-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00607-z","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"24 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: \u201cIn the sentence beginning \u2018In the context of...\u2019 in the Abstract section of the article, the text \u2018In the context of a fellowship at the European Medicines Agency\u2019 should have read \u2018In the context of the European Medicines Agency collaborating expert program\u201d.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40290-026-00616-y","URL":"https:\/\/doi.org\/10.1007\/s40290-026-00616-y","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Olaf Witt serves as advisory board member for Novartis, Ipsen, BMS Janssen and receives research grant support from Day One Biopharmaceuticals and BioMed Valley Discoveries. Cornelis van Tilburg reports serving on advisory boards for Alexion, Bayer, Novartis, and Roche, receiving travel support from Eli Lilly, lecture honoraria from Ipsen, and received research grants from BioMed Valley Discoveries and Day One Biopharmaceuticals. All activities were outside the submitted work. Laura Fankhauser, Franca Ligas, Giovanni Lesa, Anette Solli Karlsen, Marianne Lunzer, Monique Al, Sabine Scherer, Sylvie Benchetrit, Claudia Riedel, Annette Kopp-Schneider, Ruth Witt, and Dominik Karres declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data analysed in this study were accessed through special administrator privileges in the Clinical Trial Information System (CTIS) and contain confidential regulatory information. While information about approved clinical trials are publicly available via the EMA website (\n                      \n                      ), detailed assessment data used in this analysis are not publicly accessible due to confidentiality requirements between the regulatory authorities and the sponsor of the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Ethics approval was not required as this study involved retrospective analysis of anonymised regulatory assessment data without access to individual patient information. The analysis was conducted within the framework of an official EMA fellowship with appropriate data access permissions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Laura Fankhauser, Ruth Witt, Olaf Witt, Dominik Karres and Cornelis van Tilburg conceptualised the study. Laura Fankhauser conducted all analyses of Clinical Trial Applications in CTIS, developed and implemented the analytical methodology, created all figures and visualisations, and wrote the first draft of the manuscript. Franca Ligas, Giovanni Lesa and Dominik Karres contributed to data interpretation from the EMA perspective. Anette Solli Karlsen, Marianne Lunzer, Monique Al, Sabine Scherer, Claudia Riedel and Sylvie Benchetrit provided national regulatory expertise and contributed to data interpretation from a national competent authority perspective. Annette Kopp-Schneider performed the statistical analyses. Cornelis van Tilburg and Dominik Karres supervised the study and critically reviewed and edited all versions of the manuscript. All authors reviewed and approved the final version of the manuscript and had full access to all the data in the study. Laura Fankhauser and Cornelis van Tilburg verified the underlying data.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the EMA or one of its committees or working parties.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}